347 results on '"Michalova K."'
Search Results
2. Incidence, Risk Factors, and Outcomes of Rhegmatogenous Retinal Detachment after Intravitreal Injections of Anti-VEGF for Retinal Diseases
3. Multilineage involvement and not multilineage dysplasia differentiates more precisely two basic biological categories of acute myeloid leukaemias: 316
4. Interstitial del(14)(q) involving IGH: a novel recurrent aberration in B-NHL
5. FREQUENCY AND CLINICAL IMPACT OF COMPLEX KARYOTYPES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS): S12-65
6. Multicolor flow cytometry in children with MDS and SAA. Correlation with disease category and WT1 expression: 7
7. Advanced childhood MDS: a complex karyotype but not monosomy 7 is an independent prognostic factor: 3
8. Achievement of LW or IM-1 risk score prior SCT may be connected with prolonged DFS in patients with advanced MDS
9. PS1330 VARIABILITY IN THE EXTENT OF DEL(5Q) AND ITS CLINICAL IMPLICATION IN MYELODYSPLASTIC SYNDROMES (MDS)
10. PB1651 INFERIOR PROGNOSIS OF TLX3 GENE REARRANGEMENTS IN PEDIATRIC T-ALL
11. PB2076 MOLECULAR CYTOGENETIC ANALYSIS OF CHROMOSOME 7 ABERRATIONS IN MYELOID DISEASES
12. Bilateral diffuse uveal melanocytic proliferation associated with bladder cancer: A novel imaging finding.
13. P047 Determining of intensity methylation in the area of promoter gene P15INK4B as prognostic marker in patients with myelodysplastic syndromes (MDS)
14. P026 A limited benefit of isolated 5q deletion on prognosis – results of a long term retrospective analysis
15. C011 Gene methylation, telomere length and activity of telomerase reflect the disease activity in MDS patients and may help to assess an individual risk of patients
16. C010 Differentially expressed genes of CD34+ between patients with early and advanced myelodysplastic syndrome
17. ASXL1 gene alterations in patients with isolated 20q deletion
18. MiR-155/miR-150 network regulates progression through the disease phases of chronic lymphocytic leukemia
19. R-CHOP/R-HDAC AND RITUXIMAB MAINTENANCE RESULTS IN HIGH COMPLETE REMISSION RATE, MINIMAL RESIDUAL DISEASE NEGATIVITY, AND EXCELLENT SURVIVAL IN ELDERLY MCL PATIENTS
20. Cytogenetic Clonal Evolution in Myelodysplastic Syndromes (MDS) with Isolated Del(5Q)
21. MDS Patients with Del(5Q) and Trisomy 8 in Two Independent Clones Have High fli-1 and Cereblon Messenger RNA Levels
22. Lenalidomide Treatment in Lower Risk MDS – The Experience of One Czech Center (Positive Effect of Erythropoietin ± Prednisone Addition)
23. High Level of Full-Length Cereblon Messenger RNA and Protein is Important for Lenalidomide Efficacy in Lower Risk MDS Patients
24. 80 - Occurrence of penile intraepithelial neoplasia in histological samples from circumcisions
25. Intravitreal triamcinolone: Efficacy and complications of different methods of drug delivery.
26. Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic
27. 49 THE PROGNOSTIC SIGNIFICANCE OF TP53 MUTATIONS IN MDS PATIENTS WITH DEL(5Q)
28. 170 MECHANISM OF FORMATION OF COMPLEX CHROMOSOMAL ABERRATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS): CLONAL EVOLUTION OR CHROMOTHRIPSIS?
29. 42 THE EFFICACY OF LENALIDOMIDE IN LOWER RISK MYELODYSPLASTIC SYNDROME WITH ISOLATED 5Q DELETION IS DEPENDENT ON HIGH LEVEL OF FULL-LENGTH CEREBLON MESSENGER RNA
30. 106 PATIENTS WITH TWO UNRELATED CLONES DEL(5Q) AND TRISOMY 8 – A SUBTYPE OF 5Q- SYNDOME? UNCERTAIN PROGNOSIS OF PATIENTS WITH DECREASED DEL(5Q) CLONE DUE TO LENALIDOMIDE
31. Complex karyotype newly defined: the strongest prognostic factor in advanced childhood myelodysplastic syndrome
32. Advanced childhood MDS: a complex karyotype but not monosomy 7 is an independent prognostic factor
33. 112 - 18-FDG PET-MRI in diagnostics of penile cancer, first experience
34. 227 - High Level of Full-Length Cereblon Messenger RNA and Protein is Important for Lenalidomide Efficacy in Lower Risk MDS Patients
35. 228 - MDS Patients with Del(5Q) and Trisomy 8 in Two Independent Clones Have High fli-1 and Cereblon Messenger RNA Levels
36. 191 - Lenalidomide Treatment in Lower Risk MDS – The Experience of One Czech Center (Positive Effect of Erythropoietin ± Prednisone Addition)
37. 90 - Cytogenetic Clonal Evolution in Myelodysplastic Syndromes (MDS) with Isolated Del(5Q)
38. NORs and Their Transcription Competence during the Cell Cycle
39. Report from the European myeloma network on interphase FISH in multiple myeloma and related disorders
40. Complex karyotype newly defined: The strongest prognostic factor in advanced childhood myelodysplastic syndrome
41. P230 BCR/ABL protein may be associated with an acute leukaemia phenotype
42. P-220 A comparison of effect of stem cell transplantation (SCT) with different treatment approaches on long term survival of MDS patients
43. P-231 The role of Fli1 and p53 for the effective megakaryopoiesis in 5q-syndrome
44. Interstitial deletion 9q22.32-q33.2 associated with additional familial translocation t(9;17)(q34.11;p11.2) in a patient with Gorlin-Goltz syndrome and features of Nail-Patella syndrome
45. 274 The response of FLi1, EKLF, TP53 (p53), PU.1, MDM2 gene expression in 5q- syndrome to lenalidomide treatment
46. 175 Czech MDS Group experience with azacitidine in treatment of high risk MDS and AML patients
47. 247 miRNA expression profiling in 5q- syndrome patients treated with lenalidomide
48. 228 Lenalidomide treatment of patients with 5q- syndrome affects genes located in the TNF pathway
49. 250 Are Fli1, EKLF, PU.1, HDM2 and TP53 factors implicated in refractory anemia and megakaryopoiesis in 5q- syndrome?
50. 301 Thrombocytopenia at diagnosis as an important negative prognostic marker in isolated 5q- MDS (IPSS low and Intermediate-1)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.